Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Preventing bone loss in patients who are undergoing androgen ablation for prostate
cancer may decrease the risk of fractures and may help patients live more comfortably. It is
not yet known whether calcium is more effective with or without estrogen and/or risedronate
in preventing osteoporosis.
PURPOSE: Randomized phase III trial to compare the effectiveness of two forms of calcium with
or without estrogen and/or risedronate in preventing osteoporosis in patients with prostate
cancer who are receiving androgen ablation therapy.